No quarterly revenue total was found in Tempest Therapeutics, Inc.'s SEC filings.
Tempest Therapeutics, Inc. (TPST) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$2.8 million. As of Jun 30, 2026 it held $779,000 in cash and investments and $7.6 million in total debt.
Revenue
—
Net income
$-5.24M
+33.4% vs year-ago quarter
Operating cash flow
$-2.78M
+67.0% vs year-ago quarter
Free cash flow
$-2.78M
+67.0% vs year-ago quarter
EPS
$-0.34
+83.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
15.98M
+260.1% vs year-ago quarter
Net cash
$-6.78M
Q2 FY2026
Operating margin
-20266.7%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TPST (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Brisbane, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1544227
- Former names
- Millendo Therapeutics, Inc. (until Jul 1, 2021); OvaScience, Inc. (until Dec 6, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$5.2M | -$27.7M | -$4.1M | -$3.6M | -$8.0M |
| Net income | -$5.2M | -$27.7M | -$4.0M | -$3.5M | -$7.9M |
| Diluted EPS | -$0.34 | -$2.53 | -$0.82 | -$0.79 | -$2.07 |
| Operating cash flow | -$2.8M | -$7.6M | -$3.6M | -$6.8M | -$8.4M |
| Free cash flow | -$2.8M | -$7.6M | -$3.6M | -$6.8M | -$8.4M |
| Total assets | $9.6M | $10.7M | $16.9M | $17.1M | $24.5M |
| Total liabilities | $10.7M | $9.9M | $10.3M | $10.8M | $14.7M |
| Stockholders' equity | -$1.1M | $822,000 | $6.7M | $6.3M | $9.8M |
| Cash and investments | $779,000 | $1.8M | $7.7M | $7.5M | $14.3M |
| Total debt | $7.6M | $7.9M | $8.1M | $8.4M | $8.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| ARS | Annual report to shareholders | Nov 2, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change
|
Oct 30, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Shareholder vote results, Other events
|
Oct 20, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 19, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Material agreement, Officer or director change, Regulation FD disclosure
|
Sep 28, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Sep 17, 2026 | Sep 14, 2026 |
All 1000 Tempest Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.